In non-diabetic adults with obesity, subcutaneous semaglutide reduced mean body weight by 11.62 kg compared with placebo in a meta-analysis.
In plain wordsIn adults with obesity but without diabetes, subcutaneous semaglutide lowered body weight by about 11.62 kg compared with placebo.
- Peptide
- Semaglutide
- Outcome
- DecreaseMean body weight change
- Study
n = 2,882
- Comparator
- Placebo
- Outcome group
- Body weight · Metabolic and weight
- Studied dose
- Dose not stated · subcutaneousAs given in this study (human).
Measurements
- Mean body weight change
- −11.62 kg
- semaglutide vs placebo
Source sentences
Patients treated with semaglutide experienced a clinically significant reduction in mean body weight - 11.62 kg (95% CI: -13.03 to -10.21; P < 0.00001).
2 context sentences(design, population, supporting numbers)
Efficacy of subcutaneous semaglutide compared to placebo for weight loss in obese, non-diabetic adults: a systematic review & meta-analysis.
The initial search identified 332 relevant articles and ultimately retained four randomized controlled trials encompassing 2,882 participants with a BMI ≥ 27 kg/m2.